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Abstract: Epilepsy is a common disease with significant morbidity and mortality.   Approximately 
one-third of patients with epilepsy are refractory to available seizure medications, emphasizing 
the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as 
retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. 
Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium 
channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 
600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with 
ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic 
symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. 
Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting 
a need for three-times-a-day administration. Ezogabine exhibits minimal   interactions with other 
seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical   applications 
in other medical conditions beyond epilepsy, such as neuropathic pain,   neuromyotonia, and 
bipolar disease, but these are based primarily on experimental models.
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Introduction
Epilepsy is a common disease with a cumulative lifetime risk of at least 3%.1 The 
majority of patients with epilepsy have partial seizures, accounting for about two-
thirds of cases in epidemiologic studies in developed countries.2 The burden of 
disease is also quite high, involving significant morbidity and mortality. Individuals 
with epilepsy in developed countries have an up to three-fold increase in mortality 
compared with the general population.3 Adults with seizures have also been found to 
have lower levels of education, higher rates of unemployment as well as higher rates 
of physical ailments.4 While the aim of epilepsy treatment is complete seizure control 
with minimal adverse events from medication, approximately one-third of patients 
will have persistent seizures despite antiepileptic drug (AED) treatment and can be 
classified as medically intractable.5,6
Ezogabine is an ethyl N-(2-amino-4-[{4-fluorophenyl}methylamino]phenyl 
  carbamate) (Figure 1). Previously known as D-23129, it is also known by the inter-
national nonproprietary name of retigabine in Europe and most of the world, but the 
adopted name in the United States is ezogabine. This drug was recently approved by 
the US Food and Drug Administration (FDA) and the European Medicines Agency for 
adjunctive treatment of partial-onset seizures in adults. It appears to work by a unique 
mechanism of action compared with other currently available AEDs.Neuropsychiatric Disease and Treatment 2011:7
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Figure 1 Chemical structure of ezogabine.
Table 1 Summary of efficacy data from randomized, double-blind, placebo-controlled trials of ezogabine as adjunctive treatment of 
refractory partial seizures in adults
Study/outcome measure Placebo Ezogabine
600 mg/d 900 mg/d 1200 mg/d
Porter et al23 n = 96 n = 99 n = 95 n = 106
Median change in seizure frequency, % –13.1 –23.4a –29.3a –35.2a
Patients with .50% seizure reduction, % 15.6 23.2 31.6a 33.0a
RESTORE 2 (Brodie et al24) n = 170 n = 179 n = 175
Median change in seizure frequency, % –15.9 –27.9a –39.9a
Patients with .50% seizure reduction, % 18.9 38.6a 47.0a
RESTORE 1 (French et al25) n = 152 n = 153
Median change in seizure frequency, % –17.5 –44.3a
Patients with .50% seizure reduction, % 17.8 44.4a
Note: aStatistically significant difference compared to the placebo group.
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Mechanism of action
Ezogabine exerts its anticonvulsant effects through a novel 
mechanism of action that is unique among existing AEDs. 
In particular, ezogabine activates potassium currents in 
neurons,7 which should lead to hyperpolarization of the 
membrane potential and decreased neuronal excitability 
under physiological conditions. On the molecular level, 
ezogabine enhances the activation of a specific heteromeric 
potassium channel, consisting of KCNQ2 or KCNQ3 chan-
nel subunits, a member of the Kv7 family of potassium 
channels.8,9 Ezogabine binds to the activation gate or within 
the pore of the channel itself to stabilize the channel in the 
open position.10–12 KCNQ2/3 channels mediate a previously 
described potassium current, the M-current, in neurons. The 
M-current possesses unique electrophysiological properties, 
including slow activation and deactivation near the resting 
membrane potential, which cause a decrease in repetitive 
firing of neurons under excitatory conditions. While the 
M-current had previously been shown to be blocked by a 
number of pharmacological agents, such as the acetylcholine 
agonist, muscarine (and thus the origin of the name “M” 
current), ezogabine is the first reported drug that enhances 
opening of this channel,13,14 with the associated potential for 
anticonvulsant activity.
In addition to modulating potassium channels, ezogabine 
may have other mechanisms of action. There is minimal 
evidence of a clinically significant effect of ezogabine on 
voltage-gated sodium and calcium channels.15 However, 
ezogabine may interact with GABAA (γ -aminobutyric acid 
type A) receptors,16 although this effect may require relatively 
high concentrations and thus may only represent a minor 
contribution to the anticonvulsant actions of ezogabine.15
Prior to clinical studies of ezogabine in epilepsy patients, 
ezogabine was shown to be effective in a variety of animal 
models of seizures. For example, ezogabine displays efficacy 
in the traditional antiepileptic screening assays of acutely 
induced seizures: the electrically induced maximal electro-
shock seizure and chemical convulsant penetylenetetrazole 
models in rats or mice.17 Ezogabine also has anticonvul-
sant properties in genetic animal models of epilepsy.17,18 
In   addition to direct anticonvulsant effects in suppressing 
seizures, ezogabine may also have antiepileptogenic proper-
ties in delaying the development of seizures in the kindling 
model of epilepsy.19
Interestingly, genetic mutations in the KCNQ2/3 potas-
sium channels have been identified as the cause of cases of 
benign familial neonatal convulsions.20–22 Defective potassium 
channel function represents a rational mechanistic explana-
tion for brain hyperexcitability and seizures in this inherited 
epilepsy syndrome. Since ezogabine enhances the function of 
KCNQ2/3 channels, ezogabine represents a rare example in 
which a seizure medication may directly target the underlying 
molecular defect causing a specific type of epilepsy.
Efficacy
There have been three placebo-controlled, multicenter 
studies to assess safety and efficacy in adults (Table 1). All 
of these studies were performed on patients aged 18–75. 
In all of these studies, ezogabine was used as adjunctive 
therapy in patients with refractory partial seizures, who were Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
411
Ezogabine as treatment for epilepsy
already on at least one or two other AEDs, such as   valproate, 
  carbamazepine,   phenytoin, topiramate,   lamotrigine, 
  gabapentin,   oxcarbazepine, benzodiazepines, or   barbiturates. 
The first of these studies looked at multiple   dosing   schedules, 
600, 900, and 1200 mg/day, administered three times 
daily.23 Based on this study, the FDA   recommended two 
  confirmatory studies. RESTORE 2 addressed dosages of 
600 and 900 mg/day administered three times daily,24 and 
RESTORE 1 addressed the dosage of 1200 mg/day divided 
three times daily.25
In the first study there was an 8-week forced-titration 
phase, followed by an 8-week maintenance phase. A total of 
537 subjects entered baseline, and 399 were randomized to 
a study treatment. 396 were included in an intention-to-treat 
analysis. The primary endpoint analyzed was change from 
baseline in monthly seizure frequency and was compared 
across all treatment arms. A secondary endpoint was 
responder rate, which was defined as a $50% reduction 
in seizure frequency. Seizure-free rates were not reported. 
When looking at median percentage change in monthly 
total seizure frequency, a significant dose-dependent effect 
was seen in the primary endpoint across all treatment 
groups: 600 mg/day (–23.4%), 900 mg/day (–29.3%), and 
1200 mg/day (–35.2%) vs placebo (–13.1%).23 Significant 
responder rates in the secondary endpoint were seen com-
pared with placebo in various forms of statistical analysis, 
with ranges from 23%–41%.23 This effect did also appear 
to be dose dependent with   significant effects in the 900 and 
1200 mg/day groups.23
In RESTORE 2, there were four phases: a prospective 
8-week baseline, 4-week titration, 12-week maintenance, 
and a 4-week transition phase if patients elected to par-
ticipate in the open-label extension phase. The primary 
efficacy measure for the FDA was change in total par-
tial seizure frequency per 28 days between baseline and 
double-blind period in the treated patients vs placebo. An 
intention-to-treat analysis was used. A total of 696 patients 
were screened and 539 randomized. A total of 538 patients 
were included in the intention-to-treat analysis. The median 
percentage reduction was higher for both the 600 mg/day 
(27.9%, P = 0.007) and 900 mg/day (39.9%, P , 0.001) 
groups than placebo (15.9%).24 A significant responder rate 
(.50% reduction in seizure frequency) was seen in both the 
600 mg/day (38.6%) and the 900 mg/day group (47.0%) as 
compared with placebo (18.9%, P , 0.001).24 Three to five 
percent of patients in the treatment groups became seizure-
free, although this was not statistically significant compared 
with the placebo group.
In RESTORE 1, there were two phases: an 8-week, 
prospective baseline phase and an 18-week double-blind 
treatment period (6-week initial dose titration phase). 
There were two primary endpoints: percentage change in 
28-day total partial seizure frequency between baseline and 
double-blind period, and responder rate ($50% reduction in 
28-day total partial seizure frequency between baseline and 
maintenance phase). A total of 442 patients were screened 
and 306 were randomized. A total of 305 patients were 
used in the intention-to-treat analysis. Median percentage 
reduction in monthly seizure frequency was 44.3% in the 
treated group (1200 mg/day) vs 17.5% in the placebo group 
(P , 0.001).25 Responder rate was 44.4% in the treated 
group vs 17.8% in the placebo group (P , 0.001).25 Five 
percent of patients in the treated group were seizure-free 
during the maintenance phase compared with 1% in the 
placebo group, a   difference that was not quite statistically 
significant. However, the   percentage of seizure-free days 
in the treated group was significantly greater than in the 
placebo group.
Overall, the published placebo-controlled multicenter 
studies indicate that ezogabine is effective as an adjunctive 
therapy for adults with refractory partial seizures. However, 
very few patients became seizure-free on ezogabine, and the 
degree of reduction in seizure frequency is comparable to 
most other AEDs studied as add-on therapy for intractable 
epilepsy. Furthermore, future studies are needed to assess the 
potential efficacy of ezogabine for the pediatric population 
and for other seizure types or epilepsy syndromes, such as 
generalized seizures.
Safety
Data on the safety and side effects of ezogabine were also 
derived from the three placebo-controlled, multicenter 
studies testing ezogabine as adjunctive therapy in adult 
patients with refractory partial seizures (Table 2). In the 
first study, common adverse events (.10%) could be mostly 
categorized as central nervous system (CNS) effects and 
occurred more   frequently in the ezogabine arms. These 
included somnolence, confusion, dizziness, tremor, amnesia, 
thinking abnormal, vertigo, and speech disorder.23 In the 
second study, common adverse effects (.10%) all could 
be categorized again as CNS effects and were described 
as dizziness, somnolence, headache, and fatigue.24 In the 
third study, CNS effects were again the most common, with 
40.5% complaining of dizziness and 31.4% complaining of 
somnolence in the ezogabine group.25 Additional common 
treatment emergent adverse events were fatigue, confusion, Neuropsychiatric Disease and Treatment 2011:7
Table 2 Summary of common adverse events (.10% of patients) 
reported  in  ezogabine-treated  patients  from  randomized, 
double-blind, placebo-controlled trials as adjunctive treatment of 
refractory partial seizures in adults
Dizziness
Somnolence
Fatigue
Confusion
Headache
Dysarthria
Tremor
Vertigo
Ataxia
Amnesia
Thinking abnormal
Speech disorder
Blurry vision
Asthenia
Nausea
Urinary tract infection
Source: Porter et al,23 Brodie et al,24 French et al.25
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Pharmacology
Ezogabine is metabolized primarily in the liver by acetylation 
to the mono-acetylated metabolite AWD21–360 and more 
significantly by glucuronidation to an N-glucuronide28–31 with 
subsequent predominant renal clearance. The cytochrome 
P450 system does not appear to play a significant role in 
the metabolism of ezogabine.29 Glucuronidation appears to 
be predominantly by the UGT1A1, UGT1A9, and less so, 
UGT1A4 enzymes.30,31
A variety of studies have assessed the pharmacokinetics 
of ezogabine with the majority of the data being obtained in 
a study by Ferron et al that assessed the pharmacokinetics of 
ezogabine at multiple doses up to 700 mg/day in 45 healthy 
male volunteers.32 It is rapidly absorbed after oral administra-
tion, with a peak plasma concentration at 1.5 hours.32 With 
food, maximal plasma concentration is delayed to approxi-
mately 2 hours. Mean terminal half-life was 8 hours.32 Oral 
clearance was 0.7 L/hour/kg in white subjects and volume of 
distribution was 8.7 L/kg.32 In black subjects, clearance and 
volume of distribution were 25% and 30% lower,   respectively.32 
  Pharmacokinetics was linearly dose proportional for both ezoga-
bine and the metabolite AWD21–360.32 No clinically significant 
effect has been seen with gender.33 However, a decreased rate 
of clearance has been observed in elderly subjects, possibly 
related to decline in renal function.33
Drug interactions
In vitro studies have demonstrated little or no potential for 
ezogabine to inhibit the major cytochrome P450 isoenzymes. 
No clinically significant interactions have been found between 
ezogabine and propofol, valproate, lamotrigine, or imip-
ramine.31 An in vivo study of 29 healthy volunteers given 
both lamotrigine and ezogabine demonstrated some limited 
interactions.34 In the presence of lamotrigine, ezogabine rate 
of clearance was slightly decreased, possibly due to competi-
tion for renal clearance.34 Interestingly, lamotrigine clearance 
was slightly increased, raising the possibility that ezogabine 
acted as an inductor of glucuronidation.34 An in vivo study has 
demonstrated lack of interaction between phenobarbitone and 
ezogabine.35 In clinical   studies, no significant   pharmacokinetic 
effect has been seen on phenytoin,   carbamazepine, valproic 
acid, or topiramate.36 Finally, one study showed women on 
a maintenance dose of ezogabine 750 mg/day for 19 days 
as well as a combination oral contraceptive did not have a 
decrease in contraceptive hormone exposure, suggesting lack 
of clinically significant interaction.36 Overall, ezogabine has 
minimal clinically significant interactions with other AEDs, 
as well as other drugs metabolized by the P450 system.
dysarthria, ataxia, blurred vision, and tremor. Nausea was 
also reported in 10.5% of ezogabine patients compared with 
6.6% in the placebo group.25 This was higher than seen in 
the RESTORE 2 study, at 6.1% in the 600 mg/day group 
and 6.7% in the 900 mg/day group.24 Urinary tract infections 
were seen in 11.8% of subjects on ezogabine compared with 
8.6% in the placebo group.25
As ezogabine has been demonstrated to have effects on 
bladder function in a rat model, extra attention was paid 
to urinary system side effects in RESTORE 1 and 2.26,27 
In RESTORE 2, three patients on ezogabine experienced 
chromaturia (occasional reddish-brown discoloration of 
urine) and three patients exited the study because of adverse 
events of the urinary tract (one nephritis and two urinary 
retention).24 In RESTORE 1, it was observed that 15 of the 
ezogabine-treated patients had increased post-void residual 
volumes of .100 mL compared with six of the placebo-
treated patients.25 Other adverse events observed included 
urinary tract infection, urinary hesitation, dysuria, and 
chromaturia, all of which were infrequent but occurred more 
commonly in the ezogabine-treated group than placebo.25
In summary, common adverse events of ezogabine are 
CNS effects, with the most common of these being dizziness 
and somnolence. All adverse events appeared to have some 
dose dependency. No significant cardiac, hematologic, or 
liver adverse events have been reported.23–25 Some attention 
should be paid to potential adverse effects on the urinary 
tract. There are no reported safety data in the pediatric 
population.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Other clinical applications
A variety of additional clinical applications beyond   epilepsy 
have been proposed for ezogabine. One logical   consideration is 
the possibility of treatment of peripheral nerve   hyperexcitability 
with ezogabine. The role of potassium channels in some forms 
of peripheral nerve   hyperexcitability has been understood for 
some time. For instance, Isaac’s syndrome, a disorder that 
includes   neuromyotonia, has been found in some cases to 
be autoimmune with   anti-  voltage-gated potassium channel 
antibodies.37   Interestingly, two   families have been described 
with both benign familial neonatal convulsions and myo-
kymia, supportive of KCNQ2/3 mutations as causative.38,39 
Furthermore, a single case has been reported of peripheral 
nerve hyperexcitability, secondary to a KCNQ2 mutation.40 
Interestingly, in this same case report, an in vitro study was 
performed that demonstrated potential beneficial effect of 
ezogabine on peripheral nerve   hyperexcitability.40 As some 
familial cases of episodic ataxia have also been attributed to 
potassium channel mutations, theoretically, ezogabine may 
represent a rational treatment for ataxia in these cases, although 
  published clinical data are lacking.
Based on rat models, ezogabine has also been proposed 
as a potential treatment for neuropathic pain,41,42 mania,43 
and addiction to psychostimulants.44 Another rodent model 
  demonstrated a possible antidystonic effect.45 An in vitro 
study has demonstrated a possible anxiolytic effect of 
ezogabine.46 As remarked above, ezogabine has been studied 
in a rat model to look at effects on bladder function, with 
resultant suggestion that it may be effective for detrusor 
overactivity.26,27
Conclusion
Epilepsy is a significant cause of morbidity and mortality, 
with approximately one-third of patients being refractory to 
available medications. Ezogabine is a new potential treatment 
that has a unique mechanism of action consisting of activat-
ing KCNQ2/3 channels. It demonstrates reasonable efficacy 
for adjunctive partial seizure control, although ezogabine 
appears to make few intractable patients seizure-free and has 
similar effects on seizure frequency as other AEDs tested 
as add-on therapy for refractory epilepsy. Based on clinical 
trials, ezogabine appears to be relatively safe and well toler-
ated, although long-term post-marketing surveillance data are 
needed. Furthermore, while there have been minimal serious 
or life-threatening adverse events reported, it has potential 
for significant urologic side effects. Early data demonstrate 
minimal interaction with medications other than lamotrigine. 
Future studies may demonstrate whether ezogabine will play 
a role in other neuropsychiatric or even urologic diseases. 
In addition, further studies are being considered at this time 
for ezogabine’s role in the treatment of pediatric partial 
epilepsy and Lennox–Gastaut syndrome.36
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